Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ianalumab + Eltrombopag in Primary ITP (VAYHIT2)
NCT05653219Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2023
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
A Phase 3 trial of ianalumab in primary immune thrombocytopenia (ITP), sponsored by Novartis. Started Feb 2023; status: active, not recruiting.
02
Drugs
ianalumab
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05653219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05653219.